“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (hATTR) amyloidosis with polyneuropathy in Turkey where we currently don’t have
Zolgensma also delivered the desired results in patients who were given presymptomatic treatment and also in certain participants aged over five years. The gene therapy could sustain durability
VaxCelerate is a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). Hoth and Voltron, with the
At the recommendation of an independent data monitoring committee (IDMC), and per the prespecified interim analysis plan, due to positive efficacy results at the first interim analysis for
The company, which is a subsidiary of Roche, will evaluate the safety and efficacy of Actemra given intravenously plus standard of care in hospitalised adults with severe COVID-19
CABENUVA is now the first once-monthly, complete long-acting regimen for the treatment of HIV-1 in adults, which has been indicated to replace the current antiretroviral (ARV) regimen in
The company has closed a $45 million Series A financing led by SR One, with participation from Cormorant Asset Management, Quan Capital and WestRiver Group, to advance its
A rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, SMA results in the rapid and irreversible loss of motor neurons, affecting muscle functions,
The late-stage study assessed the safety and efficacy of abrocitinib in adult patients with the skin condition, who were also on background topical therapy. According to Pfizer, the
The findings were published in two online articles ahead of print in The New England Journal of Medicine. The primary endpoints were achieved in all three trials. Namely,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.